Literature DB >> 7539702

Intrapleural mitoxantrone for the palliative treatment of malignant pleural effusions.

M Morales1, M C Expósito.   

Abstract

A group of 21 patients with malignant pleural effusions were treated with the instillation of 40 mg mitoxantrone intrapleurally, after complete fluid drainage. There was a 100% complete response rate with no toxic effects (0%). The mean survival of the patients was 57.1 weeks.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7539702     DOI： 10.1007/bf00365856

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  6 in total

1.  Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone).

Authors:  G Groth; U Gatzemeier; K Häussingen; M Heckmayr; H Magnussen; R Neuhauss; J V Pavel
Journal:  Ann Oncol       Date:  1991-03       Impact factor: 32.976

2.  Treatment of malignant pleural effusion: a method using tube thoracostomy and talc.

Authors:  R H Adler; I Sayek
Journal:  Ann Thorac Surg       Date:  1976-07       Impact factor: 4.330

Review 3.  Diagnosis and treatment of malignant pleural effusion.

Authors:  F H Hausheer; J W Yarbro
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

4.  Intracavitary bleomycin for the control of malignant effusions.

Authors:  J D Bitran; C Brown; R K Desser; M F Kozloff; C Shapiro; A A Billings
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

5.  Intracavitary bleomycin in the management of malignant effusions.

Authors:  W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

6.  In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.

Authors:  D S Alberts; L Young; N Mason; S E Salmon
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929
  6 in total
  6 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Authors:  Katherina-Bernadette Sreter; Marko Jakopovic; Zoran Janevski; Miroslav Samarzija; Paul Zarogoulidis; Ioannis Kioumis; Nikolaos Mparmpetakis; Athanasia Pataka; Konstantinos Zarogoulidis; Theodora Tsiouda; Christoforos Kosmidis; Sofia Mpaka; Haidong Huang; Wolfgang Hohenforst-Schmidt; Charalampos Charalampidis; Nikolaos Machairiotis; Bojan Zaric; Aleksandar Milovancev
Journal:  Ann Transl Med       Date:  2016-05

Review 3.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

4.  Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.

Authors:  R W Light; N S Wang; J A Despars; S E Gruer; C Sassoon; F S Vargas
Journal:  Lung       Date:  1996       Impact factor: 2.584

5.  Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.

Authors:  Nikolaos Barbetakis; Theodoros Antoniadis; Christodoulos Tsilikas
Journal:  World J Surg Oncol       Date:  2004-05-20       Impact factor: 2.754

6.  Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.

Authors:  Nikolaos Barbetakis; Michalis Vassiliadis; Konstantinos Kaplanis; Rosalia Valeri; Christodoulos Tsilikas
Journal:  BMC Palliat Care       Date:  2004-09-09       Impact factor: 3.234
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.